In 2022, Lexicon achieved success when the FDA approved sotagliflozin under the brand name Inpefa for heart failure, but type 1 diabetes has proven to be a more elusive indication.

An FDA advisory committee voted Thursday that it didn’t believe the benefits of Lexicon Pharmaceuticals’ (NASDAQ:LXRX) drug sotagliflozin ... under the brand name Inpefa.

Lexicon is commercially launching one of these medicines, INPEFA® (sotagliflozin) in the United States, and has a pipeline of other promising drug candidates in discovery and clinical and ...